Real-World Effectiveness of Mavacamten in Canada (MAVEN)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Treatments: Drug: Mavacamten

Study type: Observational

Funder types: Industry

Identifiers

NCT06338202

CV027-1137

Details and patient eligibility

About

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have initiated mavacamten, as part of routine clinical care, through the Bristol Myers Squibb CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
• Adult patient (≥18 years of age or as defined per local province/territory) at Index Date (first prescribed dose of mavacamten).
• Patient has been diagnosed with symptomatic oHCM of New York Heart Association (NYHA) class II to III at the time of mavacamten initiation.

Exclusion criteria

• In the 6 weeks prior to baseline (i.e., Index Date; date of first prescribed dose of mavacamten), patient has received any cardiac myosin inhibitor (including mavacamten) for oHCM or any other medical condition as part of a clinical trial.

Trial design

115 participants in 1 patient group

Patients treated with mavacamten

Description:

Patients with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care

Treatment:

Drug: Mavacamten